Adjuvant levamisole and fluorouracil in high risk colorectal cancer patients

1996 ◽  
Author(s):  
O Merimsky ◽  
M Inbar ◽  
M Gutman ◽  
S Chaitchik
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 393
Author(s):  
Alexander Hendricks ◽  
Anu Amallraja ◽  
Tobias Meißner ◽  
Peter Forster ◽  
Philip Rosenstiel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Standard Of Care ◽  
High Risk Patients ◽  
Risk Patients ◽  
Individualized Treatments ◽  
Colorectal Cancer Patients

Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.

18 F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients

2014 ◽  
Vol 83 (12) ◽  
pp. 2224-2230 ◽  
Author(s):  
Germán Andrés Jiménez Londoño ◽  
Ana María García Vicente ◽  
Victoria Sánchez Pérez ◽  
Fátima Jiménez Aragón ◽  
Alberto León Martin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Colorectal Cancer Patients

A Smad4-modulated Wnt target gene expression profile identifies high-risk colorectal cancer patients

2012 ◽  
Vol 215 (3) ◽  
pp. S30-S31
Author(s):  
J. Joshua Smith ◽  
Tanner J. Freeman ◽  
Xi Chen ◽  
Natasha G. Deane ◽  
Mary K. Washington ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Target Gene ◽  
Target Gene Expression ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document